Overall, Eisai generated 601.2 billion yen (nearly $4 billion) over the last nine months of 2024, signaling 9% growth year-on-year. For the entire 12-month stretch ending March 31, the company ...

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and Lenvima didn’t exactly go their way. The Keytruda-Lenvima regimen ...

Jan 31 (Reuters) - The European medicines regulator said on Friday it will review safety information for Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Leqembi, nearly three ...

Jan 24 (Reuters) - Merck (MRK.N), opens new tab and Japan-based Eisai (4523.T), opens new tab said on Friday a combination of their therapies failed to extend the lives of patients with a type of ...

TOKYO -- Japanese drugmaker Eisai will make its Alzheimer's disease treatment Leqembi available for at-home administration by fiscal 2025 in the U.S., where thousands of patients are waiting to ...

Biogen and Eisai have hit another bump in their quest to win European regulatory approval of their Alzheimer's drug Leqembi. The companies on Friday said the European Commission has asked the ...

The International Committee of Tourism Film Festivals (CIFFT) and the United Nations World Tourism Organization (UN Tourism) have signed a Memorandum of Understanding (MoU) to advance sustainable ...

The MoU signed between Dr. S Selvakumar, Principal Secretary of the Commerce and Industries Department of Karnataka, and Dharshan Shanthamurthy, Founder & CEO of SISA. The Karnataka government on ...

Photo Credit: Kalyani Strategic Systems Limited (KSSL), a wholly-owned subsidiary of Bharat Forge Limited, has entered into a Memorandum of Understanding (MoU) with L3Harris Technologies to ...